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Nanoparticulate systems for neurotrophic factor delivery
are currently studied in an attempt to solve some of
the challenges in neurodegenerative disease treatment.
Nanomedicine for brain disorders has faced difficulties in
cerebral administraton of fragile neurotrophic proteins
and high costs. According to recent studies, the signaling
protein brain-derived neurotrophic factor (BDNF), being a
main mammalian neurotrophin, is regarded as a therapeu-
tic target for a number of neurodegenerative and psychia-
tric diseases (Huntington’s disease, Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, depres-
sion, schizophrenia, etc). However, a beneficial BDNF
treatment is still not clinically available for patients.
Thanks to their safety and feasibility for large-scale pro-
duction, lipid nanoparticles (NPs) and nanostructured
vehicles are considered as key candidates for delivery of
BDNF-based therapeutics. Nanoparticles may serve as
reservoirs for controlled drug release and may influence
the biodistribution and bioavailability of the administered
protein. Nanoencapsulation in lipid particles provides pro-
tein stabilization against degradation and a possibility for
targeted delivery. Lipid nanostructure types and liquid-
crystalline phase transformations are suggested to govern
the cell uptake mechanisms. Fusogenic lipids, like the
cubic-phase forming monoolein, characterized by pore-
inducing propensity and significant structural influence on
biomembranes, have drawn the attention in designing
BDNF delivery vehicles. Nanoparticles were prepared from
self-assembly mixtures of lipids and BDNF and functiona-
lized by stabilizing amphiphilic polymer derivatives.
The resulting nanoscale organizations were revealed by
cryogenic transmission electron microscopy (cryo-TEM)
and X-ray structural analysis (SAXS) in order to evaluate
the ability of the investigated particles for protein upload.
The interaction of differentiated human neuroblastoma
SH-SY5Y cells (a cellular model of neurodegeneration)
with lipid nanocarriers of BDNF was studied by means of
confocal fluorescence microscopy imaging. The obtained
nanoparticles, encapsulating neurotrophic protein, may be
anticipated to show therapeutic potential in repairing
damaged neurons by regulation of the neuronal survival
and plasticity.
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